Document:

Exhibit 10.1

 

SHARE EXCHANGE AGREEMENT

 

This SHARE EXCHANGE
AGREEMENT (this “Agreement”), dated as of December 30th, 2013, is by and among UCP Holdings, Inc.,
a Nevada corporation (“UCP”), Kapital Yonetim Hizmet Ve Gayrimenkul Yatirim Sanayi Ticaret Ltd. Sirketi, a
Turkish limited liability company (“Kapital”), and the shareholder of Kapital identified on Annex A
hereto (the “Shareholder”). Each of the parties to this Agreement is individually referred to herein as a “Party”
and collectively, as the “Parties.” Capitalized terms used herein that are not otherwise defined herein shall
have the meanings ascribed to them in Annex B hereto.

 

BACKGROUND

 

Kapital has 4,000,000,000
common shares (the “Kapital Stock”) outstanding, 2,040,000,000 of which the Shareholder holds and has agreed
to sell subject to the terms and conditions of this Agreement, which constitutes 51% of the issued and outstanding capital stock
of Kapital. The Shareholder has agreed to transfer these 2,040,000,000 shares ofKapital Stock in exchange for an aggregate of
36,500,000 newly issued shares of the Common Stock, par value $0.0001 per share, of UCP (the “UCP Stock”),
which will constitute approximately 48% of the issued and outstanding capital stock of UCP as of and immediately after the Closing.The
number of shares of UCP Stock to be received by the Shareholder is listed opposite the Shareholder’s name on Annex A
and is referred to herein as the “Shares.”

 

The Board of Directors
of each of UCP and Kapital has determined that it is desirable to effect this share exchange.

 

AGREEMENT

 

NOW, THEREFORE, in
consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth herein, and
intending to be legally bound hereby, the Parties agree as follows:

 

ARTICLE I

Exchange of Shares

 

1.1.          Exchange
by the Shareholder. At the Closing, the Shareholder shall sell, transfer, convey, assign and deliver to UCP their Kapital
Stock in the amounts set forth on Annex A free and clear of all Liens in exchange for the UCP Stock listed on Annex
A opposite the Shareholder’s name.

 

1.2.          Closing. The
closing (the “Closing”) of the transactions contemplated hereby (the “Transactions”) shall
take place at the offices of Kapital commencing at 9:00 a.m. local time on the second business day following the satisfaction
or waiver of all conditions to the obligations of the Parties to consummate the Transactions (other than conditions with respect
to actions that the respective parties will take at Closing),or such other date and time as the Parties may mutually determine
(the “Closing Date”).

 

    	-1-

    	 

    

 

ARTICLE II

Representations and Warranties of Shareholder

 

The Shareholder hereby
represent and warrant to UCP as follows:

 

2.1.          Good
Title. The Shareholder are the record and beneficial owners, and have and shall transfer at the Closing good and marketable
title to theirKapital Stock shown as owned of record by Shareholder on Annex A hereto, with the right and authority to
sell and deliver such Kapital Stock. Upon delivery of any certificate or certificates duly assigned, representing the same as
herein contemplated and/or upon registering of UCP as the new owner of such Kapital Stock, UCP will receive good title to such
Kapital Stock, free and clear of all Liens.

 

2.2.          Pre-emptive
Rights. The Shareholder have no pre-emptive rights or any other rights to acquire any Kapital Stock that have not been
waived or exercised.

 

2.3.          Residency. The
Shareholder areindividuals resident in Turkey.

 

2.4.          Power
and Authority. The Shareholder have the legal power and authority to execute and deliver this Agreement and to perform
their obligations hereunder. All acts required to be taken by the Shareholder to enter into this Agreement and to carry out the
Transactions have been properly taken. This Agreement constitutes a legal, valid and binding obligation of the Shareholder, enforceable
against the Shareholder in accordance with the terms hereof.

 

2.5.          No
Conflicts. The execution and delivery of this Agreement by the Shareholder and the performance by the Shareholder of
their obligations hereunder in accordance with the terms hereof: (a) will not require the consent of any third party or Governmental
Entity under any Laws; (b) will not violate any Laws applicable to the Shareholder and (c) will not violate or breach any contractual
obligation to which the Shareholder are a party.

 

2.6.          Litigation. There
is no pending proceeding against such Shareholder that involves the Shares or that challenges, or may have the effect of preventing,
delaying or making illegal, or otherwise interfering with, any of the transactions contemplated by this Agreement and, to the
knowledge of the Shareholder, no such proceeding has been threatened, and no event or circumstance exists that is reasonably likely
to give rise to or serve as a basis for the commencement of any such proceeding.

 

2.7.          No
Finder’s Fee. The Shareholder have not created any obligation for any finder’s, investment banker’s
or broker’s fee in connection with the Transactions.

 

2.8.          Purchase
Entirely for Own Account. The UCP Stock proposed to be acquired by the Shareholder hereunder will be acquired for investment
for its own account, and not with a view to the resale or distribution of any part thereof, and the Shareholder have no present
intention of selling or otherwise distributing the UCP Stock, except in compliance with applicable securities laws.

  

    	-2-

    	 

    

  

2.9.          Available
Information. The Shareholder have such knowledge and experience in financial and business matters that it is capable
of evaluating the merits and risks of investment in UCP and has had full access to all the information it considers necessary
or appropriate to make an informed investment decision with respect to the UCP Stock.

 

2.10.         Non-Registration. The
Shareholder understand that the UCP Stock has not been registered under the Securities Act and, if issued in accordance with the
provisions of this Agreement, will be issued by reason of a specific exemption from the registration provisions of the Securities
Act which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the Shareholder’
representations as expressed herein. The non-registration shall have no prejudice with respect to any rights, interests, benefits
and entitlements attached to the UCP Stock in accordance with UCP’s charter documents or the laws of its jurisdiction of
incorporation.

 

2.11.         Restricted
Securities. The Shareholder understand that the UCP Stock is characterized as “restricted securities” under
the Securities Act inasmuch as this Agreement contemplates that, if acquired by the Shareholder pursuant hereto, the UCP Stock
would be acquired in a transaction not involving a public offering. The Shareholder further acknowledge that if the UCP Stock
is issued to the Shareholder in accordance with the provisions of this Agreement, such UCP Stock may not be resold without registration
under the Securities Act or the existence of an exemption therefrom. The Shareholder represent that they are familiar with Rule
144 promulgated under the Securities Act, as presently in effect, and understands the resale limitations imposed thereby and by
the Securities Act.

 

2.12.         Accredited
Investor. The Shareholder are “accredited investors” within the meaning of Rule 501 under the Securities
Act and the Shareholder were not organized for the specific purpose of acquiring the UCP Stock.

 

2.13.         Regulation
S. No offer to enter into this Agreement has been made by UCP to the Shareholder in the United States. Neither the Shareholder
nor any of their respective affiliate or any person acting on their behalf or on behalf of any such affiliate, has engaged or
will engage in any activity undertaken for the purpose of, or that reasonably could be expected to have the effect of, conditioning
the markets in the United States for the UCP Stock, including, but not limited to, effecting any sale or short sale of securities,
prior to the expiration of any restricted period contained in Regulation S promulgated under the Securities Act (any such activity
being defined herein as a “Directed Selling Effort”). To the best knowledge of the Shareholder, this Agreement
and the transactions contemplated herein are not part of a plan or scheme to evade the registration provisions of the Securities
Act, and the UCP Stock is being acquired for investment purposes by the Shareholder. The Shareholder agree that all offers and
sales of the UCP Stock from the date hereof and through the expiration of any restricted period set forth in Rule 903 of Regulation
S (as the same may be amended from time to time hereafter) shall not be made to U.S. Persons (within the meaning of Regulation
S) or for the account or benefit of U.S. Persons and shall otherwise be made in compliance with the provisions of Regulation S
and any other applicable provisions of the Securities Act. Neither the Shareholder or any of their representatives has conducted
any Directed Selling Effort as that term is used and defined in Rule 902 of Regulation S and neither of them nor any of their
respective representatives will engage in any such Directed Selling Effort within the United States through the expiration of
any restricted period set forth in Rule 903 of Regulation S.

  

    	-3-

    	 

    

  

2.14.         Legends. It
is understood that the UCP Stock will bear the following legend or one that is substantially similar to the following legend:

 

NEITHER THESE SECURITIES NOR
THE SECURITIES ISSUABLE UPON CONVERSION OF THESE SECURITIES HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR
THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE
TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THESE SECURITIES AND THE SECURITIES
ISSUABLE UPON CONVERSION OF THESE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT SECURED BY SUCH SECURITIES.

 

Additionally, the UCP Stock will bear
any legend required by the “blue sky” laws of any state to the extent such laws are applicable to the securities represented
by the certificate so legended.

 

2.15.         Opinion. The
Shareholder shall not transfer any or all of the UCP Stock pursuant to Regulation S or absent an effective registration statement
under the Securities Act and applicable state securities law covering the disposition of Shareholder’s UCP Stock, without
first providing UCP with an opinion of counsel (which counsel and opinion are reasonably satisfactory to UCP) to the effect that
such transfer will be made in compliance with Regulation S or will be exempt from the registration and the prospectus delivery
requirements of the Securities Act and the registration or qualification requirements of any applicable U.S. state securities
laws.

 

2.16.         Consent. Shareholder
understand and acknowledge that UCP may refuse to transfer the UCP Stock, unless Shareholder comply with this Section 2.17 and
any other restrictions on transferability set forth in Annexes C and D. The Shareholder consent to UCP making a notation on its
records or giving instructions to any transfer agent of UCP’s common stock in order to implement the restrictions on transfer
or transfer upon conversion of the UCP Stock.

 

2.17.         Disclosure. This
Agreement, the schedules hereto and any certificate attached hereto or delivered in accordance with the terms hereof by or on
behalf of the Shareholder in connection with the transactions contemplated by this Agreement, when taken together, do not contain
any untrue statement of a material fact or omit any material fact necessary in order to make the statements contained herein and/or
therein not misleading.

 

ARTICLE III

Representations and Warranties of Kapital

 

Subject to the exceptions
set forth in the Kapital Disclosure Letter (regardless of whether or not the Kapital Disclosure Letter is referenced below with
respect to any particular representation or warranty), Kapitalrepresents and warrants as follows to UCP.

 

    	-4-

    	 

    

 

3.1.          Organization,
Standing and Power. Kapital is duly organized, validly existing and in good standing under the laws of the jurisdiction
in which it is organized and has the corporate power and authority and possesses all governmental franchises, licenses, permits,
authorizations and approvals necessary to enable it to own, lease or otherwise hold its properties and assets and to conduct its
businesses as presently conducted, other than such franchises, licenses, permits, authorizations and approvals the lack of which,
individually or in the aggregate, has not had and would not reasonably be expected to have a material adverse effect on Kapital,
a material adverse effect on the ability of Kapitalto perform its obligations under this Agreement or on the ability of Kapitalto
consummate the Transactions (a “Kapital Material Adverse Effect”). Kapitalis duly qualified to do business
in each jurisdiction where the nature of its business or its ownership or leasing of its properties make such qualification necessary
except where the failure to so qualify would not reasonably be expected to have a Kapital Material Adverse Effect. Kapital has
delivered to UCP true and complete copies of the Kapital Constituent Instruments, and the comparable charter, organizational documents
and other constituent instruments of each of its subsidiaries, in each case as amended through the date of this Agreement.

 

3.2.          Kapital
Subsidiaries; Equity Interests.

 

(a)          Except
as set forth on Schedule 3.2, Kapital does not as of the date of this Agreement own, directly or indirectly, any capital stock
or other securities of, or have any beneficial ownership interest in, or hold any equity or similar interest, or have any investment
in any corporation, limited liability company, partnership, limited partnership, joint venture or other company, person or other
entity.

 

3.3           Capital
Structure. The issued and outstanding capital stock of Kapital consists of 1,220,842,287common shares. Except as set
forth above, no shares of capital stock or other voting securities of Kapital are issued, reserved for issuance or outstanding.
Kapital is the sole record and beneficial owner of all of the issued and outstanding capital stock of each of its subsidiaries.All
outstanding shares of the capital stock of Kapital and each of its subsidiaries are validly issued, fully paid and nonassessable
and not subject to or issued in violation of any purchase option, call option, right of first refusal, preemptive right, subscription
right or any similar right under any provision of the applicable corporate laws of Turkey, the Kapital Constituent Instruments
or any Contract to which Kapital is a party or otherwise bound. There are not any bonds, debentures, notes or other indebtedness
of Kapitalor any of its subsidiaries having the right to vote (or convertible into, or exchangeable for, securities having the
right to vote) on any matters on which holders of Kapital Stock or the capital stock of any of its subsidiaries may vote (“Voting
Kapital Debt”). As of the date of this Agreement, there are not any options, warrants, rights, convertible or exchangeable
securities, “phantom” stock rights, stock appreciation rights, stock-based performance units, commitments, Contracts,
arrangements or undertakings of any kind to which Kapitalor any of its subsidiaries is a party or by which any of them is bound
(a) obligating Kapitalor any of its subsidiaries to issue, deliver or sell, or cause to be issued, delivered or sold, additional
shares of capital stock or other equity interests in, or any security convertible or exercisable for or exchangeable into any
capital stock of or other equity interest in, Kapitalor any of its subsidiaries or any Voting Kapital Debt, (b) obligating Kapitalor
any of its subsidiaries to issue, grant, extend or enter into any such option, warrant, call, right, security, commitment, Contract,
arrangement or undertaking or (c) that give any person the right to receive any economic benefit or right similar to or derived
from the economic benefits and rights occurring to holders of the capital stock of Kapital or of any of its subsidiaries. As of
the date of this Agreement, there are not any outstanding contractual obligations of Kapital to repurchase, redeem or otherwise
acquire any shares of capital stock of Kapital.

  

    	-5-

    	 

    

  

3.4.          Authority;
Execution and Delivery; Enforceability. Kapitalhas all requisite corporate power and authority to execute and deliver
this Agreement and to consummate the Transactions. The execution and delivery by Kapitalof this Agreement and the consummation
by Kapitalof the Transactions have been duly authorized and approved by the Board of Directors of Kapitaland no other corporate
proceedings on the part of Kapitalare necessary to authorize this Agreement and the Transactions. When executed and delivered,
this Agreement will be enforceable against Kapitalin accordance with its terms.

 

3.5.          No
Conflicts; Consents.

  

(a)          The
execution and delivery by Kapitalof this Agreement does not, and the consummation of the Transactions and compliance with the
terms hereof will not, conflict with, or result in any violation of or default (with or without notice or lapse of time, or both)
under, or give rise to a right of termination, cancellation or acceleration of any obligation or to loss of a material benefit
under, or result in the creation of any Lien upon any of the properties or assets of Kapitalunder, any provision of (i) the Kapital
Constituent Instruments or the comparable charter or organizational documents of any of its subsidiaries, (ii) any Contract to
which Kapitalis a party or by which any of its properties or assets is bound or (iii) subject to the filings and other matters
referred to in Section 3.5(b), any material judgment, order or decree or material Law applicable to Kapitalor its properties or
assets, including without limitation, the Kapital Stock, other than, in the case of clauses (ii) and (iii) above, any such items
that, individually or in the aggregate, have not had and would not reasonably be expected to have a Kapital Material Adverse Effect.

 

(b)          Except
as set forth in the Kapital Disclosure Letter and for required filings with the SEC and applicable “Blue Sky” or state
securities commissions, no Consent of, or registration, declaration or filing with, or permit from, any Governmental Entity is
required to be obtained or made by or with respect to Kapitalin connection with the execution, delivery and performance of this
Agreement or the consummation of the Transactions.

 

3.6.          Taxes.

  

(a)          Kapitalhas
timely filed, or has caused to be timely filed on its behalf, all Tax Returns required to be filed by it, and all such Tax Returns
are true, complete and accurate, except to the extent any failure to file or any inaccuracies in any filed Tax Returns, individually
or in the aggregate, have not had and would not reasonably be expected to have a Kapital Material Adverse Effect. All Taxes shown
to be due on such Tax Returns, or otherwise owed, have been timely paid, except to the extent that any failure to pay, individually
or in the aggregate, has not had and would not reasonably be expected to have a Kapital Material Adverse Effect. There are no
unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of Kapitalknow
of no basis for any such claim.

 

    	-6-

    	 

    

 

(b)          The
Kapital Financial Statements reflect an adequate reserve for all Taxes payable by Kapital(in addition to any reserve for deferred
Taxes to reflect timing differences between book and Tax items) for all Taxable periods and portions thereof through the date
of such financial statements. No deficiency with respect to any Taxes has been proposed, asserted or assessed against Kapitalor
any of its subsidiaries, and no requests for waivers of the time to assess any such Taxes are pending, except to the extent any
such deficiency or request for waiver, individually or in the aggregate, has not had and would not reasonably be expected to have
a Kapital Material Adverse Effect.

 

3.7.          Benefit
Plans.

  

(a)          Except
as set forth in the Kapital Disclosure Letter, Kapitaldoes not have or maintain any collective bargaining agreement or any bonus,
pension, profit sharing, deferred compensation, incentive compensation, stock ownership, stock purchase, stock option, phantom
stock, retirement, vacation, severance, disability, death benefit, hospitalization, medical or other plan, arrangement or understanding
(whether or not legally binding) providing benefits to any current or former employee, officer or director of Kapital(collectively,
“Kapital Benefit Plans”). As of the date of this Agreement there are not any severance or termination agreements
or arrangements between Kapitaland any current or former employee, officer or director of Kapital, nor doesKapitalhave any general
severance plan or policy.

 

(b)          Since
December 31, 2012, there has not been any adoption or amendment in any material respect by Kapitalof any Kapital Benefit Plan.

 

(c)          Neither
the consummation of the transactions contemplated hereby alone, nor in combination with another event, with respect to each director,
officer, employee and consultant of Kapital, will result in (a) any payment (including, without limitation, severance, unemployment
compensation or bonus payments) becoming due from Kapital, (b) any increase in the amount of compensation or benefits payable
to any such individual or (c) any acceleration of the vesting or timing of payment of compensation payable to any such individual.
No agreement, arrangement or other contract of Kapitalprovides benefits or payments contingent upon, triggered by, or increased
as a result of a change in the ownership or effective control of Kapital.

 

3.8.          Litigation. There
is no Action against or affecting Kapitalor any of its properties which (a) adversely affects or challenges the legality, validity
or enforceability of any of this Agreement or the Shares or (b) could, if there were an unfavorable decision, individually or
in the aggregate, have or reasonably be expected to result in a Kapital Material Adverse Effect. Neither Kapital, nor any director
or officer thereof (in his or her capacity as such), is or has been the subject of any Action involving a claim or violation of
or liability under central or provincial securities laws or a claim of breach of fiduciary duty.

  

    	-7-

    	 

    

 

 

3.9.          Compliance
with Applicable Laws. Except as would not have a Kapital Material Adverse Effect, the business and operations of Kapitalhas
been and is being conducted in accordance with all applicable foreign, federal, state and local laws, rules and regulations and
all applicable orders, injunctions, decrees, writs, judgments, determinations and awards of all courts and governmental agencies
and instrumentalities. Except as would not have a Kapital Material Adverse Effect, Kapitalis not, and is not alleged to be, in
violation of, or (with or without notice or lapse of time or both) in default under, or in breach of, any term or provision of
the Kapital Companies’ charter documents or of any indenture, loan or credit agreement, note, deed of trust, mortgage, security
agreement or other material agreement, lease, license or other instrument, commitment, obligation or arrangement to which Kapitalis
a party or by which Kapital’s properties, assets or rights are bound or affected. To the best knowledge of Kapital, no other
party to any material contract, agreement, lease, license, commitment, instrument or other obligation to which Kapitalis a party
are (with or without notice or lapse of time or both) in default thereunder or in breach of any term thereof. Kapitalis not subject
to any obligation or restriction of any kind or character, nor are there, to the knowledge of Kapital, any event or circumstance
relating to Kapitalthat materially and adversely affects in any way its business, properties, assets or prospects or that would
prevent or make burdensome their performance of or compliance with all or any part of this Agreement or the consummation of the
transactions contemplated hereby or thereby. This Section 3.9 does not relate to matters with respect to Taxes, which are the
subject of Section 3.6.

 

3.10.         Brokers;
Schedule of Fees and Expenses. Except as disclosed in the Kapital Disclosure Letter, no broker, investment banker, financial
advisor or other person is entitled to any broker’s, finder’s, financial advisor’s or other similar fee or commission
in connection with the Transactions based upon arrangements made by or on behalf of Kapital.

 

3.11.         Contracts. Except
as disclosed in the Kapital Disclosure Letter, there are no Contracts that are material to the business, properties, assets, condition
(financial or otherwise), results of operations or prospects of Kapitaltaken as a whole. Kapitalis not in violation of or in default
under (nor does there exist any condition which upon the passage of time or the giving of notice would cause such a violation
of or default under) any Contract to which it is a party or by which it or any of its properties or assets are bound, except for
violations or defaults that would not, individually or in the aggregate, reasonably be expected to result in a Kapital Material
Adverse Effect.

 

3.12.         Title
to Properties. Except as set forth in the Kapital Disclosure Letter, Kapitaldoes not own any real property. Kapitalhas
sufficient title to, or valid leasehold interests in, all of its properties and assets used in the conduct of its businesses.
All such assets and properties, other than assets and properties in which Kapitalhas leasehold interests, are free and clear of
all Liens, except for Liens that, in the aggregate, do not and will not materially interfere with the ability of Kapitalto conduct
business as currently conducted.

 

3.13.         Intellectual
Property. Kapitalowns, or is validly licensed or otherwise has the right to use, all Intellectual Property Rights which
are material to the conduct of the business of Kapitaltaken as a whole. The Kapital Disclosure Letter sets forth a description
of all Intellectual Property Rights which are material to the conduct of the businesses of Kapitaltaken as a whole. There are
no claims pending or, to the knowledge of any of Kapital, threatened that Kapitalis infringing or otherwise adversely affecting
the rights of any person with regard to any Intellectual Property Right. To the best knowledge of Kapital, no person is infringing
the rights of Kapitalwith respect to any Intellectual Property Right.

  

3.14.         Labor
Matters. There are no collective bargaining or other labor union agreements to which any of Kapitalis a party or by which
it is bound. No material labor dispute exists or, to the best knowledge of Kapital, is imminent with respect to any of the employees
of Kapital.

  

    	-8-

    	 

    

  

3.15.         Financial
Statements. Kapital has delivered to UCP its unaudited financial statements for the fiscal years ended December 31, 2012
and 2011 and its unaudited financial statements for the six months ended June 30, 2013 (collectively, the “Kapital Financial
Statements”). The Kapital Financial Statements have been prepared in accordance with [generally accepted accounting
principles] applied on a consistent basis throughout the periods indicated. The Kapital Financial Statements fairly present in
all material respects the financial condition and operating results of Kapital, as of the dates, and for the periods, indicated
therein. Kapital does not have any material liabilities or obligations, contingent or otherwise, other than (a) liabilities incurred
in the ordinary course of business subsequent to June 30, 2013, and (b) obligations under contracts and commitments incurred in
the ordinary course of business and not required under generally accepted accounting principles to be reflected in the Kapital
Financial Statements, which, in both cases, individually and in the aggregate, would not be reasonably expected to result in a
Kapital Material Adverse Effect.

 

3.16.         Insurance. Except
as set forth in the Kapital Disclosure Letter, Kapitalare insured by insurers of recognized financial responsibility against such
losses and risks and in such amounts as are prudent and customary in the businesses in which Kapitalis engaged and in the geographic
areas where it engages in such businesses. Kapitalhas no reason to believe that it will not be able to renew its existing insurance
coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue
its business on terms consistent with market for Kapitalrespective lines of business.

 

3.17.         Transactions
with Affiliates and Employees. Except as set forth in the Kapital Disclosure Letter, no officer, director or stockholder
of any of Kapitalor any affiliate or “associate” (as such term are defined in Rule 405 of the SEC under the Securities
Act) of any such person, have or have had, either directly or indirectly, (1) an interest in any person which (a) furnishes or
sells services or products which are furnished or sold or are proposed to be furnished or sold by Kapital, or (b) purchases from
or sells or furnishes to, or proposes to purchase from, sell to or furnish Kapital any goods or services; or (2) a beneficial
interest in any contract or agreement to which Kapitalis a party or by which they may be bound or affected.

 

3.18.         Internal
Accounting Controls. Kapitalmaintains a system of internal accounting controls sufficient to provide reasonable assurance
that (a) transactions are executed in accordance with management’s general or specific authorizations, (b) transactions
are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles
and to maintain asset accountability, (c) access to assets is permitted only in accordance with management’s general or
specific authorization, and (d) the recorded accountability for assets is compared with the existing assets at reasonable intervals
and appropriate action is taken with respect to any differences. Kapitalhas established disclosure controls and procedures for
its company and designed such disclosure controls and procedures to ensure that material information relating to Kapitalis made
known to the officers by others withinKapital. The officers of Kapitalhave evaluated the effectiveness of the Kapital Companies’
controls and procedures. Since June 30, 2013, there have been no significant changes in the Kapital Companies’ internal
controls or, to Kapital’s best knowledge, in other factors that could significantly affect Kapital’s internal controls.

  

    	-9-

    	 

    

  

3.19.         Governmental
Inquiries. Kapitalhas provided to UCP a copy of each material written inspection report, questionnaire, inquiry, demand
or request for information received by Kapitalfrom any Governmental Entity, and Kapital’s response thereto, and each material
written statement, report or other document filed by Kapitalwith any Governmental Entity.

 

3.20.         Solvency. Based
on the financial condition of Kapital as of the Closing Date (and assuming that the Closing shall have occurred), (a) Kapital’s
fair saleable value of its assets exceeds the amount that will be required to be paid on or in respect of Kapital’s existing
debts and other liabilities (including known contingent liabilities) as they mature, (b) Kapital’s assets do not constitute
unreasonably small capital to carry on its business for the current fiscal year as now conducted and as proposed to be conducted
including its capital needs taking into account the particular capital requirements of the business conducted by Kapital, and
projected capital requirements and capital availability thereof, and (c) the current cash flow of Kapital, together with the proceeds
Kapital would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would
be sufficient to pay all amounts on or in respect of its debt when such amounts are required to be paid. Kapital does not intend
to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable
on or in respect of its debt).

 

3.21.         Application
of Takeover Protections. Kapital has taken all necessary action, if any, in order to render inapplicable any control
share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover
provision under the Kapital Constituent Instruments or the laws of its jurisdiction of organization that is or could become applicable
to the Shareholder as a result of the Shareholder and Kapital fulfilling their obligations or exercising their rights under this
Agreement, including, without limitation, the issuance of the Shares and the Shareholder’ ownership of the Shares.

 

3.22.         No
Additional Agreements. Kapital does not have any agreement or understanding with the Shareholder with respect to the
Transactions other than as specified in this Agreement.

 

3.23.         Investment
Company. Kapital is not an affiliate of, and immediately following the Closing will not have become, an “investment
company” within the meaning of the Investment Company Act of 1940, as amended.

 

3.24.         Disclosure. Kapitalconfirms
that neither it nor any person acting on its behalf has provided the Shareholder or their agents or counsel with any information
that it believes constitutes material, non-public information except insofar as the existence and terms of the proposed transactions
hereunder may constitute such information and except for information that will be disclosed by UCP under a current report on Form
8-K filed within four business days after the Closing. Kapital understands and confirms that the Shareholder will rely on the
foregoing representations and covenants in effecting transactions in securities of Kapital. All disclosure provided to UCP regarding
Kapital, its business and the Transactions, furnished by or on behalf of Kapital(including Kapital’s representations and
warranties set forth in this Agreement) is true and correct and does not contain any untrue statement of a material fact or omit
to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they
were made, not misleading.

 

3.25.         Information
Supplied. None of the information supplied or to be supplied by Kapital for inclusion or incorporation by reference in
the Form 8-K filing contains any untrue statement of a material fact or omits to state any material fact required to be stated
therein or necessary in order to make the statements therein, in light of the circumstances under which they are made, not misleading.

  

    	-10-

    	 

    

  

3.26.         Absence
of Certain Changes or Events. Except as disclosed in the Kapital Financial Statements or in the Kapital Disclosure Letter,
from June 30, 2013 to the date of this Agreement, Kapital have conducted its business only in the ordinary course, and during
such period there has not been:

 

(a)          any
change in the assets, liabilities, financial condition or operating results of Kapital, except changes in the ordinary course
of business that have not caused, in the aggregate, a Kapital Material Adverse Effect;

 

(b)          any
damage, destruction or loss, whether or not covered by insurance, that would have a Kapital Material Adverse Effect;

 

(c)          any
waiver or compromise by Kapital of a valuable right or of a material debt owed to it;

 

(d)          any
satisfaction or discharge of any lien, claim, or encumbrance or payment of any obligation by Kapital, except in the ordinary course
of business and the satisfaction or discharge of which would not have a Kapital Material Adverse Effect;

 

(e)          any
material change to a material Contract by which Kapitalor any of its assets is bound or subject;

 

(f)          any
mortgage, pledge, transfer of a security interest in, or lien, created by Kapital, with respect to any of its material properties
or assets, except liens for taxes not yet due or payable and liens that arise in the ordinary course of business and do not materially
impair Kapital’s ownership or use of such property or assets;

 

(g)          any
loans or guarantees made by Kapitalto or for the benefit of its employees, officers or directors, or any members of their immediate
families, or any loans or advances to any persons, corporations, business trusts, associations, companies, partnerships, limited
liability companies, joint ventures and other entities, governments, agencies and political subdivision other than travel advances
and other advances made in the ordinary course of its business;

 

(h)          any
alteration of Kapital’s method of accounting or the identity of its auditors;

 

(i)          any
declaration or payment of dividend or distribution of cash or other property to the Shareholder or any purchase, redemption or
agreements to purchase or redeem any Kapital Stock;

 

(j)          any
issuance, sale, disposition or encumbrance of equity securities to any officer, director or affiliate, except pursuant to existing
Kapital stock option plans, or any change in its outstanding shares of capital stock or its capitalization, whether by reason
of reclassification, recapitalization, stock split, combination, exchange or readjustment of shares, stock dividend or otherwise;
or

  

    	-11-

    	 

    

 

(k)          any
arrangement or commitment by Kapitalto do any of the things described in this Section 3.26.

 

3.27.      No
Undisclosed Events, Liabilities, Developments or Circumstances. No event, liability, development or circumstance has
occurred or exists, or is contemplated to occur with respect to Kapital, or its business, properties, prospects, operations or
financial condition, that would be required to be disclosed by Kapital under applicable securities laws on a registration statement
on Form S-1 filed with the SEC relating to an issuance and sale by Kapital of its Kapital Stock and which has not been publicly
announced. All debts, obligations or liabilities with respect to directors and officers of Kapitalwill be cancelled prior to the
Closing.

 

3.28.      Foreign
Corrupt Practices. Neither Kapital, nor, to the Kapital’s best knowledge, any director, officer, agent, employee
or other person acting on behalf of Kapitalhas, in the course of its actions for, or on behalf of, Kapital(a) used any corporate
funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (b) made any
direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; (c) violated
or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended; or (d) made any unlawful bribe,
rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government official or employee.

 

3.29.      Environmental
and Safety Matters. Except as set forth in the Kapital Disclosure Letter and except as would not have a Kapital Material
Adverse Effect:

 

(a)          Kapitalhas
at all time been and are in compliance with all Environmental Laws applicable to Kapital.

 

(b)          There
are no Actions pending or threatened against Kapitalalleging the violation of any Environmental Law or environmental permit applicable
to Kapitalor alleging that Kapitalis potentially responsible parties for any environmental site contamination.

 

(c)          Neither
this Agreement nor the consummation of the transactions contemplated by this Agreement shall impose any obligations to notify
or obtain the consent of any Governmental Entity or third parties under any Law or other requirement relating to the environment,
natural resources, or public or employee health and safety (“Environmental Laws”) applicable to Kapital.

 

ARTICLE IV

Representations and Warranties of UCP

 

Subject to the exceptions
set forth in the UCP Disclosure Letter or the SEC Reports (regardless of whether or not the UCP Disclosure Letter or the SEC Reportsare
referenced below with respect to any particular representation or warranty) or the SEC Reports, UCP represents and warrants as
follows to the Shareholder and Kapital.

 

    	-12-

    	 

    

 

4.1.          Organization,
Standing and Power. UCP is duly organized, validly existing and in good standing under the laws of the State of Nevada
and has full corporate power and authority and possesses all governmental franchises, licenses, permits, authorizations and approvals
necessary to enable it to own, lease or otherwise hold its properties and assets and to conduct its businesses as presently conducted,
other than such franchises, licenses, permits, authorizations and approvals the lack of which, individually or in the aggregate,
has not had and would not reasonably be expected to have a material adverse effect on UCP, a material adverse effect on the ability
of UCP to perform its obligations under this Agreement or on the ability of UCP to consummate the Transactions (a “UCP
Material Adverse Effect”). UCP is duly qualified to do business in each jurisdiction where the nature of its business
or its ownership or leasing of its properties makes such qualification necessary and where the failure to so qualify would reasonably
be expected to have a UCP Material Adverse Effect. UCP has delivered to Kapital true and complete copies of the UCP Charter and
the UCP Bylaws.

 

4.2.          Subsidiaries;
Equity Interests.Except as set forth in the UCP Disclosure Letter or the SEC Reports,
UCP does not own, directly or indirectly, any capital stock, membership interest, partnership interest, joint venture interest
or other equity interest in any person.

 

4.3.          Capital
Structure. The authorized capital stock of UCP consists of 800,000,000 shares of common stock, par value $0.0001 per share,
and 200,000,000shares of preferred stock, par value $0.0001 per share. There are 39,500,000 shares of UCP’s common stock
and 0 shares of UCP’spreferred stock issued and outstanding. No shares
of UCP’s common stock or preferred stock are held by UCP in its treasury. Except as set forth in
the UCP Disclosure Letter or the SEC Reports, no other shares of capital stock or other voting securities of UCP were issued,
reserved for issuance or outstanding. All outstanding shares of the capital stock of UCP are, and all such shares that may be
issued prior to the date hereof will be when issued, duly authorized, validly issued, fully paid and nonassessable and not subject
to or issued in violation of any purchase option, call option, right of first refusal, preemptive right, subscription right or
any similar right under any provision of the Nevada Revised Statutes, the UCP Charter, the UCP Bylaws or any Contract to which
UCP is a party or otherwise bound. There are not any bonds, debentures, notes or other indebtedness of UCP having the right to
vote (or convertible into, or exchangeable for, securities having the right to vote) on any matters on which holders of UCP’s
common stock may vote (“Voting UCP Debt”). Except as set forth in the UCP
Disclosure Letter, there are not any options, warrants, rights, convertible or exchangeable securities, “phantom”
stock rights, stock appreciation rights, stock-based performance units, commitments, Contracts, arrangements or undertakings of
any kind to which UCP is a party or by which it is bound (a) obligating UCP to issue, deliver or sell, or cause to be issued,
delivered or sold, additional shares of capital stock or other equity interests in, or any security convertible or exercisable
for or exchangeable into any capital stock of or other equity interest in, UCP or any Voting UCP Debt, (b) obligating UCP to issue,
grant, extend or enter into any such option, warrant, call, right, security, commitment, Contract, arrangement or undertaking
or (c) that give any person the right to receive any economic benefit or right similar to or derived from the economic benefits
and rights occurring to holders of the capital stock of UCP. As of the date of this Agreement, there are not any outstanding contractual
obligations of UCP to repurchase, redeem or otherwise acquire any shares of capital stock of UCP. Except as set forth in the UCP
Disclosure Letter, UCP is not a party to any agreement granting any securityholder of UCP the right to cause UCP to register shares
of the capital stock or other securities of UCP held by such securityholder under the Securities Act. The stockholder list provided
to Kapital is a current stockholder list generated by its stock transfer agent, and such list accurately reflects all of the issued
and outstanding shares of the UCP’s common stock.

  

    	-13-

    	 

    

  

4.4.          Authority;
Execution and Delivery; Enforceability. The execution and delivery by UCP of this Agreement and the consummation by UCP of
the Transactions have been duly authorized and approved by the Board of Directors of UCP and no other corporate proceedings on
the part of UCP are necessary to authorize this Agreement and the Transactions. This Agreement constitutes a legal, valid and
binding obligation of UCP, enforceable against UCP in accordance with the terms hereof.

 

4.5.          No
Conflicts; Consents.

 

(a)          The
execution and delivery by UCP of this Agreement does not, and the consummation of Transactions and compliance with the terms hereof
will not, conflict with or result in any violation of or default (with or without notice or lapse of time, or both) under, or
give rise to a right of termination, cancellation or acceleration of any obligation or to loss of a material benefit under, or
to increased, additional, accelerated or guaranteed rights or entitlements of any person under, or result in the creation of any
Lien upon any of the properties or assets of UCP under, any provision of (i) the UCP Charter or UCP Bylaws, (ii) any material
Contract to which UCP is a party or by which any of its properties or assets is bound or (iii) subject to the filings and other
matters referred to in Section 4.5(b), any material judgment, order or decree or material Law applicable to UCP or its properties
or assets, other than, in the case of clauses (ii) and (iii) above, any such items that, individually or in the aggregate, have
not had and would not reasonably be expected to have a UCP Material Adverse Effect.

 

(b)          No
Consent of, or registration, declaration or filing with, or permit from, any Governmental Entity is required to be obtained or
made by or with respect to UCP in connection with the execution, delivery and performance of this Agreement or the consummation
of the Transactions, other than the filings with the SEC and filings under state “blue sky” laws, as may be required
in connection with this Agreement and the Transactions.

 

4.6.          SEC
Documents; Undisclosed Liabilities.

  

(a)          UCP
has filed all reports, schedules, forms, statements and other documents required to be filed by it with the SEC since September
12, 2012 pursuant to Sections 13(a), 14(a) and 15(d) of the Exchange Act (the “SEC Reports”).

 

(b)          As
of its respective filing date, each SEC Report complied in all material respects with the requirements of the Exchange Act and
the rules and regulations of the SEC promulgated thereunder applicable to such SEC Report, and did not contain any untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made, not misleading. Except to the extent that information contained
in any SEC Report has been revised or superseded by a later SEC Report, none of the SEC Reports contains any untrue statement
of a material fact or omits to state any material fact required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made, not misleading. The consolidated financial statements of UCP
included in the SEC Reports comply as to form in all material respects with applicable accounting requirements and the published
rules and regulations of the SEC with respect thereto, have been prepared in accordance with the U.S. generally accepted accounting
principles (except, in the case of unaudited statements, as permitted by the rules and regulations of the SEC) applied on a consistent
basis during the periods involved (except as may be indicated in the notes thereto) and fairly present the consolidated financial
position of UCP and its consolidated subsidiaries as of the dates thereof and the consolidated results of their operations and
cash flows for the periods shown (subject, in the case of unaudited statements, to normal year-end audit adjustments).

  

    	-14-

    	 

    

 

4.7.          Absence
of Certain Changes or Events. Except as set forth in the UCP Disclosure Letter or the
SEC Reports, from the date of the most recent audited financial statements of UCP (the “UCP Financial Statements”)
to the date of this Agreement, UCP has conducted its business only in the ordinary course, and during such period there has not
been:

 

(a)          any
change in the assets, liabilities, financial condition or operating results of UCP from that reflected in the UCP Financial Statements,
except changes in the ordinary course of business that have not caused, in the aggregate, a UCP Material Adverse Effect;

 

(b)          any
damage, destruction or loss, whether or not covered by insurance, that would have a UCP Material Adverse Effect;

 

(c)          any
waiver or compromise by UCP of a valuable right or of a material debt owed to it;

 

(d)          any
satisfaction or discharge of any lien, claim, or encumbrance or payment of any obligation by UCP, except in the ordinary course
of business and the satisfaction or discharge of which would not have a UCP Material Adverse Effect;

 

(e)          any
material change to a material Contract by which UCP or any of its assets is bound or subject;

 

(f)          any
material change in any compensation arrangement or agreement with any employee, officer, director or stockholder;

 

(g)          any
resignation or termination of employment of any officer of UCP;

 

(h)          any
mortgage, pledge, transfer of a security interest in or lien created by UCP with respect to any of its material properties or
assets, except liens for taxes not yet due or payable and liens that arise in the ordinary course of business and that do not
materially impair UCP’s ownership or use of such property or assets;

 

(i)          any
loans or guarantees made by UCP to or for the benefit of its employees, officers or directors, or any members of their immediate
families, other than travel advances and other advances made in the ordinary course of its business;

 

(j)          any
declaration, setting aside or payment or other distribution in respect of any of UCP’s capital stock, or any direct or indirect
redemption, purchase, or other acquisition of any of such stock by UCP;

 

(k)          any
alteration of UCP’s method of accounting or the identity of its auditors;

 

 

    	-15-

    	 

    

 

(l)          any
issuance of equity securities to any officer, director or affiliate, except pursuant to existing UCP stock option plans; or

 

(m)          any
arrangement or commitment by UCP to do any of the things described in this Section 4.8.

 

4.8.          Taxes.

 

(a)          Except
as set forth in the UCP Disclosure Letter, UCP has timely filed, or has caused to be timely filed on its behalf, all Tax
Returns required to be filed by it, and all such Tax Returns are true, complete and accurate, except to the extent any failure
to file, any delinquency in filing or any inaccuracies in any filed Tax Returns, individually or in the aggregate, have not had
and would not reasonably be expected to have a UCP Material Adverse Effect. All Taxes shown to be due on such Tax Returns, or
otherwise owed, have been timely paid, except to the extent that any failure to pay, individually or in the aggregate, has not
had and would not reasonably be expected to have a UCP Material Adverse Effect.

 

(b)          The
UCP Financial Statements reflect an adequate reserve for all Taxes payable by UCP (in addition to any reserve for deferred Taxes
to reflect timing differences between book and Tax items) for all Taxable periods and portions thereof through the date of such
financial statements. No deficiency with respect to any Taxes has been proposed, asserted or assessed against UCP, and no requests
for waivers of the time to assess any such Taxes are pending, except to the extent any such deficiency or request for waiver,
individually or in the aggregate, has not had and would not reasonably be expected to have a UCP Material Adverse Effect.

 

(c)          There
are no Liens for Taxes (other than for current Taxes not yet due and payable) on the assets of UCP. UCP is not bound by any agreement
or Lien under which UCP could become liable for a tax liability of any person other thanUCP.

 

4.9.          Absence
of Changes in Benefit Plans. From the date of the UCP Financial Statements to the date of this Agreement, there has not been
any adoption or amendment in any material respect by UCP of any collective bargaining agreement or any bonus, pension, profit
sharing, deferred compensation, incentive compensation, stock ownership, stock purchase, stock option, phantom stock, retirement,
vacation, severance, disability, death benefit, hospitalization, medical or other plan, arrangement or understanding (whether
or not legally binding) providing benefits to any current or former employee, officer or director of UCP (collectively, “UCP
Benefit Plans”). As of the date of this Agreement, there are not any employment, consulting, indemnification, severance
or termination agreements or arrangements between UCP and any current or former employee, officer or director of UCP, nor does
UCP have any general severance plan or policy.

 

4.10.         ERISA
Compliance; Excess Parachute Payments. UCP does not, and since its inception never has, maintained or contributed to any “employee
pension benefit plans” (as defined in Section 3(2) of ERISA), “employee welfare benefit plans” (as defined in
Section 3(1) of ERISA) or any other UCP Benefit Plan for the benefit of any current or former employees, consultants, officers
or directors of UCP.

  

    	-16-

    	 

    

  

4.11.         Litigation. There
is no Action against or affecting UCP or any subsidiary or any of their respective properties pending or, to the best knowledge
of UCP, currently threatened, which (a) adversely affects or challenges the legality, validity or enforceability of either of
this Agreement or the Shares or (b) could, if there were an unfavorable decision, individually or in the aggregate, have or reasonably
be expected to result in a UCP Material Adverse Effect. Neither UCP nor any subsidiary, nor any director or officer thereof (in
his or her capacity as such), is or has been the subject of any Action involving a claim or violation of or liability under federal
or state securities laws or a claim of breach of fiduciary duty.

 

4.12.         Compliance
with Applicable Laws. UCP is in compliance with all applicable Laws, including those relating to occupational health and safety,
the environment, export controls, trade sanctions and embargoes, except for instances of noncompliance that, individually and
in the aggregate, have not had and would not reasonably be expected to have a UCP Material Adverse Effect. UCP has not received
any written communication during the past two years from a Governmental Entity that alleges that UCP is not in compliance in any
material respect with any applicable Law. UCP is in compliance with all effective requirements of the Sarbanes-Oxley Act of 2002,
as amended, and the rules and regulations thereunder, that are applicable to it, except where such noncompliance could not have
or reasonably be expected to result in a UCP Material Adverse Effect. This Section 4.13 does not relate to matters with respect
to Taxes, which are the subject of Section 4.9.

 

4.13.         Contracts. Except
as set forth in the SEC Reports, there are no Contracts that are material to the business, properties, assets, condition (financial
or otherwise), results of operations or prospects of UCP taken as a whole. UCP is not in violation of or in default under (nor
does there exist any condition which upon the passage of time or the giving of notice would cause such a violation of or default
under) any Contract to which it is a party or by which it or any of its properties or assets is bound, except for violations or
defaults that would not, individually or in the aggregate, reasonably be expected to result in a UCP Material Adverse Effect.

 

4.14.         Title
to Properties. UCP has good title to, or valid leasehold interests in, all of its properties and assets used in the conduct
of its businesses. All such assets and properties, other than assets and properties in which UCP has leasehold interests, are
free and clear of all Liens, except for Liens that, in the aggregate, do not and will not materially interfere with the ability
of UCP to conduct business as currently conducted. UCP has complied in all material respects with the terms of all material leases
to which it is a party and under which it is in occupancy, and all such leases are in full force and effect. UCP enjoys peaceful
and undisturbed possession under all such material leases.

 

4.15.         Intellectual
Property. UCP does not own, nor is validly licensed nor otherwise has the right to use, any Intellectual Property Rights. No
claims are pending or, to the knowledge of UCP, threatened that UCP is infringing or otherwise adversely affecting the rights
of any person with regard to any Intellectual Property Right.

 

4.16.         Labor
Matters. There are no collective bargaining or other labor union agreements to which UCP is a party or by which it is bound.
No material labor dispute exists or, to the knowledge of UCP, is imminent with respect to any of the employees of UCP.

  

    	-17-

    	 

    

  

4.17.         Transactions
With Affiliates and Employees. Except as set forth in the SEC Reports, none of the officers or directors of UCP and, to the
knowledge of UCP, none of the employees of UCP is presently a party to any transaction with UCP or any subsidiary (other than
for services as employees, officers and directors), including any Contract or other arrangement providing for the furnishing of
services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any
officer, director or such employee or, to the knowledge of UCP, any entity in which any officer, director, or any such employee
has a substantial interest or is an officer, director, trustee or partner.

 

4.18.         Internal
Accounting Controls. UCP maintains a system of internal accounting controls sufficient to provide reasonable assurance that
(a) transactions are executed in accordance with management’s general or specific authorizations, (b) transactions are recorded
as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to
maintain asset accountability, (c) access to assets is permitted only in accordance with management’s general or specific
authorization, and (d) the recorded accountability for assets is compared with the existing assets at reasonable intervals and
appropriate action is taken with respect to any differences. UCP has established disclosure controls and procedures for UCP and
designed such disclosure controls and procedures to ensure that material information relating to UCP is made known to the officers
by others within those entities. UCP’s officers have evaluated the effectiveness of UCP’s controls and procedures.
Since May31, 2013, there have been no significant changes in UCP’s internal
controls or, to UCP’s knowledge, in other factors that could significantly affect UCP’s internal controls.

 

4.19.         Solvency. Based
on the financial condition of UCP as of the Closing Date (and assuming that the Closing shall have occurred), (a) UCP’s
fair saleable value of its assets exceeds the amount that will be required to be paid on or in respect of UCP’s existing
debts and other liabilities (including known contingent liabilities) as they mature, (b) UCP’s assets do not constitute
unreasonably small capital to carry on its business for the current fiscal year as now conducted and as proposed to be conducted,
including its capital needs, taking into account the particular capital requirements of the business conducted by UCP, and projected
capital requirements and capital availability thereof, and (c) the current cash flow of UCP, together with the proceeds UCP would
receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient
to pay all amounts on or in respect of its debt when such amounts are required to be paid. UCP does not intend to incur debts
beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in
respect of its debt).

 

4.20.         Application
of Takeover Protections. UCP has taken all necessary action, if any, in order to render inapplicable any control share acquisition,
business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision
under the UCP’s charter documents or the laws of its state of incorporation that is or could become applicable to the Shareholder
as a result of the Shareholder and UCP fulfilling their obligations or exercising their rights under this Agreement, including,
without limitation, the issuance of the Shares and the Shareholder’s ownership of the Shares.

 

4.21.         No
Additional Agreements. UCP does not have any agreement or understanding with the Shareholder with respect to the Transactions
other than as specified in this Agreement.

  

    	-18-

    	 

    

  

4.22.         Reserved.

  

4.23.         Disclosure. UCP
confirms that neither it nor any person acting on its behalf has provided the Shareholder or their agents or counsel with any
information that UCP believes constitutes material, non-public information except insofar as the existence and terms of the proposed
transactions hereunder may constitute such information and except for information that will be disclosed by UCP under a current
report on Form 8-K filed within four business days after the Closing. UCP understands and confirms that the Shareholder will rely
on the foregoing representations and covenants in effecting transactions in securities of UCP. All disclosure provided to the
Shareholder regarding UCP, its business and the Transactions, furnished by or on behalf of UCP (including UCP’s representations
and warranties set forth in this Agreement) is true and correct and does not contain any untrue statement of a material fact or
omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which
they were made, not misleading.

 

4.24.         Certain
Registration Matters. Except as set forth in the UCP Disclosure Letter, UCP has not granted or agreed to grant to any person
any rights (including “piggy-back” registration rights) to have any securities of UCP registered with the SEC or any
other governmental authority that have not been satisfied.

 

4.25.         Listing
and Maintenance Requirements. UCP is, and has no reason to believe that it will not in the foreseeable future continue to be,
in compliance with the listing and maintenance requirements for continued listing of the UCP Stock on the trading market on which
the UCP Stock are currently listed or quoted. The issuance and sale of the UCP Stock under this Agreement does not contravene
the rules and regulations of the trading market on which the UCP Stock are currently listed or quoted, and no approval of the
stockholders of UCP is required for UCP to issue and deliver to the Shareholder the UCP Stock contemplated by this Agreement.

 

4.26.         No
Undisclosed Events, Liabilities, Developments or Circumstances. Except as set forth in the UCP Disclosure Letter, no event,
liability, development or circumstance has occurred or exists, or is contemplated to occur with respect to UCP, its subsidiaries
or their respective businesses, properties, prospects, operations or financial condition, that would be required to be disclosed
by UCP under applicable securities laws on a registration statement on Form S-1 filed with the SEC relating to an issuance and
sale by UCP of its common stock and which has not been publicly announced.

 

4.27.         Foreign
Corrupt Practices. Neither UCP, nor to UCP’s knowledge, any director, officer, agent, employee or other person acting
on behalf of UCP has, in the course of its actions for, or on behalf of, UCP (a) used any corporate funds for any unlawful contribution,
gift, entertainment or other unlawful expenses relating to political activity; (b) made any direct or indirect unlawful payment
to any foreign or domestic government official or employee from corporate funds; (c) violated or is in violation of any provision
of the U.S. Foreign Corrupt Practices Act of 1977, as amended; or (d) made any unlawful bribe, rebate, payoff, influence payment,
kickback or other unlawful payment to any foreign or domestic government official or employee.

  

    	-19-

    	 

    

  

ARTICLE V

Deliveries

 

5.1.          Deliveries
of the Shareholder.

  

(a)          Concurrently
herewith the Shareholder are delivering to UCP and Kapital this Agreement executed by the Shareholder.

 

(b)          At
or prior to the Closing, the Shareholder shall deliver to UCP:

 

(i)          certificate(s)
representing the Kapital Stock in the amounts set forth on Annex A; and

 

(ii)         a
duly executed instrument of transfer for transfer by the Shareholder of the Kapital Stock in the amounts set forth on Annex A
to UCP.

 

5.2.          Deliveries
of UCP.

  

(a)          Concurrently
herewith, UCP is delivering Kapital and to the Shareholder, a copy of this Agreement executed by UCP.

 

(b)          At
or prior to the Closing, UCP shall deliver to Kapital:

 

(i)          a
certificate from UCP, signed by its Secretary or Assistant Secretary, certifying that the attached copies of the UCP Charter,
UCP Bylaws and resolutions of the Board of Directors of UCP approving this Agreement and the Transactions are all true, complete
and correct and remain in full force and effect;

 

(ii)         a
certificate of good standing of UCP dated within five (5) business days of Closing issued by the Secretary of State of Nevada;

 

(c)          Within
5 business days following the Closing, UCP shall deliver to the Shareholder certificate representing the Shares issued to the
Shareholder as set forth on Annex A.

 

5.3.          Deliveries
of the Kapital Companies.

  

(a)          Concurrently
herewith, Kapital is delivering to UCP and the Shareholder this Agreement executed by the Kapital Companies.

 

(b)          At
or prior to the Closing, Kapital shall deliver to UCP a certificate from Kapital, signed by its authorized officer certifying
that the attached copies of the Kapital Constituent Instruments and resolutions of the Board of Directors of Kapital approving
this Agreement and the Transactions are all true, complete and correct and remain in full force and effect.

 

(c)          At
Closing, Kapital shall deliver to UCP a legal opinion from Kapital’s legal counsel in Turkey, as required by Section 6.2(i)
below.

  

    	-20-

    	 

    

 

ARTICLE VI

Conditions to Closing

 

6.1.          UCP
Conditions Precedent. The obligations of the Shareholder and Kapital to enter into and complete the Closing are subject,
at the option of the Shareholder and the Kapital , to the fulfillment on or prior to the Closing Date of the following
conditions, any one or more of which may be waived by the Shareholder and Kapital in writing.

 

(a)          Representations
and Covenants. The representations and warranties of UCP contained in this Agreement shall be true in all material respects
on and as of the Closing Date with the same force and effect as though made on and as of the Closing Date. UCP shall have performed
and complied in all material respects with all covenants and agreements required by this Agreement to be performed or complied
with by UCP on or prior to the Closing Date. UCP shall have delivered to the Shareholder and Kapital a certificate, dated the
Closing Date, to the foregoing effect.

 

(b)          Litigation.
No action, suit or proceeding shall have been instituted before any court or governmental or regulatory body or instituted or
threatened by any governmental or regulatory body to restrain, modify or prevent the carrying out of the Transactions or to seek
damages or a discovery order in connection with such Transactions, or which has or may have, in the reasonable opinion of Kapital
or the Shareholder, a materially adverse effect on the assets, properties, business, operations or condition (financial or otherwise)
of UCP.

 

(c)          No
Material Adverse Change. There shall not have been any occurrence, event, incident, action, failure to act, or transaction
since May 31, 2013 which has had or is reasonably likely to cause a UCP Material Adverse Effect.

 

(d)          Post-Closing
Capitalization. At, and immediately after, the Closing, the authorized capitalization, and the number of issued and outstanding
shares of the capital stock of UCP shall be as indicated on a schedule to be delivered by the Parties at or prior to the Closing.

 

(e)          SEC
Reports. UCP shall have filed all reports and other documents required to be filed by it under the U.S. federal securities
laws through the Closing Date.

 

(f)          OTCQB
Quotation.UCP shall have maintained its status as a company whose common stock is quoted on the OTCQB and no reason shall
exist as to why such status shall not continue immediately following the Closing.

 

(g)          No
Suspensions of Trading in UCP Stock; Listing. Trading in the UCP Stock shall not have been suspended by the SEC or any trading
market (except for any suspensions of trading of not more than one trading day solely to permit dissemination of material information
regarding UCP) at any time since the date of execution of this Agreement, and the UCP Stock shall have been at all times since
such date listed for trading on a trading market.

 

(h)          Satisfactory
Completion of Due Diligence. Kapital and the Shareholder shall have completed their legal, accounting and business due diligence
of UCP and the results thereof shall be satisfactory to Kapital and the Shareholder in their sole and absolute discretion.

  

    	-21-

    	 

    

 

(i)          Deliveries.
The deliveries specified in Section 5.2 shall have been made by UCP.

 

6.2.          Shareholder
and Kapital Conditions Precedent.

 

The obligations of
UCP to enter into and complete the Closing is subject, at the option of UCP, to the fulfillment on or prior to the Closing Date
of the following conditions, any one or more of which may be waived by UCP in writing.

 

(a)          Representations
and Covenants. The representations and warranties of the Shareholder and Kapitalcontained in this Agreement shall be true
in all material respects on and as of the Closing Date with the same force and effect as though made on and as of the Closing
Date. The Shareholder and Kapital shall have performed and complied in all material respects with all covenants and agreements
required by this Agreement to be performed or complied with by the Shareholder and Kapitalon or prior to the Closing Date. The
Shareholder and Kapital shall have each delivered to UCP a certificate, dated the Closing Date, to the foregoing effect.

 

(b)          Litigation.
No action, suit or proceeding shall have been instituted before any court or governmental or regulatory body or instituted or
threatened by any governmental or regulatory body to restrain, modify or prevent the carrying out of the Transactions or to seek
damages or a discovery order in connection with such Transactions, or which has or may have, in the reasonable opinion of UCP,
a materially adverse effect on the assets, properties, business, operations or condition (financial or otherwise) of the Kapital
Companies.

 

(c)          No
Material Adverse Change. There shall not have been any occurrence, event, incident, action, failure to act, or transaction
since June 30, 2013 which has had or is reasonably likely to cause a Kapital Material Adverse Effect.

 

(d)          Post-Closing
Capitalization. At, and immediately after, the Closing, the authorized capitalization, and the number of issued and outstanding
shares of the capital stock of UCP shall be as indicated on a schedule to be delivered by the Parties at or prior to the Closing.

 

(e)          Satisfactory
Completion of Due Diligence.UCP shall have completed its legal, accounting and business due diligence of Kapitaland the Shareholder
and the results thereof shall be satisfactory to UCP in its sole and absolute discretion.

 

(f)          Deliveries.
The deliveries specified in Section 5.1 and Section 5.3 shall have been made by the Shareholder and the Kapital Companies, respectively.

 

(g)          Delivery
of Audit Report and Financial Statements. Kapital shall have completed and delivered to UCP the Kapital Financial Statements
and shall have received an audit report from an independent audit firm. The form and substance of the Kapital Financial Statements
shall be satisfactory to UCP in its sole and absolute discretion.

 

(h)          Audited
Financial Statements and Form 10 Disclosure. Kapital shall have provided UCP and the Shareholder with reasonable assurances
that UCP will be able to comply with its obligation to file a current report on Form 8-K within four (75) business days following
the Closing containing the requisite financial statements of Kapital.

  

    	-22-

    	 

    

 

ARTICLE VII

Covenants

 

7.1.          Preparation
of SEC Filings. UCP shall file, within four (75) business days of the Closing Date, a current report on Form 8-K and attach
as exhibits all relevant agreements with the SEC disclosing the terms of this Agreement and other requisite disclosure regarding
the Transactions and including the requisite audited consolidated financial statements of Kapital and the requisite disclosure
regarding Kapital.

 

7.2.          Public
Announcements. UCP and Kapital will consult with each other before issuing, and provide each other the opportunity to review
and comment upon, any press releases or other public statements with respect to this Agreement and the Transactions and shall
not issue any such press release or make any such public statement prior to such consultation, except as may be required by applicable
Law, court process or by obligations pursuant to any listing agreement with any national securities exchanges.

 

7.3.          Fees
and Expenses. All fees and expenses incurred in connection with this Agreement shall be paid by the Party incurring such fees
or expenses, whether or not this Agreement is consummated.

 

7.4.          Continued
Efforts. Each Party shall use commercially reasonable efforts to (a) take all action reasonably necessary to consummate the
Transactions, and (b) take such steps and do such acts as may be necessary to keep all of its representations and warranties true
and correct as of the Closing Date with the same effect as if the same had been made, and this Agreement had been dated, as of
the Closing Date.

 

7.5.          Exclusivity. Kapital
and the Shareholder shall not (a) solicit, initiate, or encourage the submission of any proposal or offer from any person relating
to the acquisition of any capital stock or other voting securities of Kapital, or any assets of Kapital(including any acquisition
structured as a merger, consolidation, share exchange or other business combination), (b) participate in any discussions or negotiations
regarding, furnish any information with respect to, assist or participate in, or facilitate in any other manner any effort or
attempt by any person to do or seek any of the foregoing, or (c) take any other action that is inconsistent with the Transactions
and that has the effect of avoiding the Closing contemplated hereby. Kapital and the Shareholder shall notify UCP immediately
if any person makes any proposal, offer, inquiry, or contact with respect to any of the foregoing.

 

7.6.          Furnishing
of Information. As long as the Shareholder own the Shares, UCP covenants to timely file (or obtain extensions in respect thereof
and file within the applicable grace period) all reports required to be filed by UCP after the date hereof pursuant to the Exchange
Act. As long as the Shareholder own the Shares, if UCP is not required to file reports pursuant to such laws, it will prepare
and furnish to the Shareholder and make publicly available in accordance with Rule 144(c) promulgated by the SEC pursuant to the
Securities Act, such information as is required for the Shareholder to sell Shares under Rule 144. UCP further covenants that
it will take such further action as the Shareholder or any subsequent holder of Shares may reasonably request, all to the extent
required from time to time to enable such person to sell Shares without registration under the Securities Act within the limitation
of the exemptions provided by Rule 144.

  

    	-23-

    	 

    

  

7.7.          Access. From
the date of this Agreement until the Closing Date, each Party shall permit representatives of any other Party to have full access
to all premises, properties, personnel, books, records (including Tax records), contracts, and documents of or pertaining to such
Party.

 

7.8.          Preservation
of Business. From the date of this Agreement until the Closing Date, each of Kapital and UCP shall operate only in the ordinary
and usual course of business consistent with its past practices, and shall use reasonable commercial efforts to (a) preserve intact
its business organization, (b) preserve the good will and advantageous relationships with customers, suppliers, independent contractors,
employees and other Persons material to the operation of its business, and (c) not permit any action or omission that would cause
any of its representations or warranties contained herein to become inaccurate or any of its covenants to be breached in any material
respect.

 

ARTICLE VIII

Miscellaneous

 

8.1.          Notices. All
notices, requests, claims, demands and other communications under this Agreement shall be in writing and shall be deemed given
upon receipt by the Parties at the following addresses (or at such other address for a Party as shall be specified by like notice):

 

If to UCP, to:

 

14 Wall Street, 20th
Floor

New York, NY 10005

Attention: Siva Pillarisetty,
CFO/Secretary

Facsimile:
212-618-1705

 

With a copy to:

 

Centarus Legal Services, PC

1821 Walden Office Square, Suite
400, Schaumburg, IL 60173

Attention: Louis Amatucci Esq.

Facsimile: 847-232-3370

 

If to Kapital, to:

 

Kapital Yonetim Hizmet Ve Gayr.
Yat. San. Tic. Ltd. Sirketi

 

Dereboyu Caddesi, Uphill Towers

A Block, 17th Floor,
Suite:107, Atasehir, 34758, Istanbul-Turkey

Attention:
Erdogan Cetin

Facsimile: +90-216-688-0435

 

    	-24-

    	 

    

 

If to the Shareholder at the addresses
set forth in Annex A hereto.

 

8.2.          Amendments;
Waivers; No Additional Consideration. No provision of this Agreement may be waived or amended except in a written instrument
signed by Kapital, UCP and the Shareholder. No waiver of any default with respect to any provision, condition or requirement of
this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any
other provision, condition or requirement hereof, nor shall any delay or omission of any Party to exercise any right hereunder
in any manner impair the exercise of any such right. No consideration shall be offered or paid to the Shareholder to amend or
consent to a waiver or modification of any provision of any Transaction Document unless the same consideration is also offered
to all Shareholder who then hold any of the Shares.

 

8.3.          Replacement
of Securities. If any certificate or instrument evidencing any Shares is mutilated, lost, stolen or destroyed, UCP shall issue
or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution therefor,
a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to UCP of such loss, theft or destruction
and customary and reasonable indemnity, if requested. The applicants for a new certificate or instrument under such circumstances
shall also pay any reasonable third-party costs associated with the issuance of such replacement Shares. If a replacement certificate
or instrument evidencing any Shares is requested due to a mutilation thereof, UCP may require delivery of such mutilated certificate
or instrument as a condition precedent to any issuance of a replacement.

 

8.4.          Remedies. In
addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, the Shareholder,
UCP and Kapitalwill be entitled to specific performance under this Agreement. The Parties agree that monetary damages may not
be adequate compensation for any loss incurred by reason of any breach of obligations described in the foregoing sentence and
hereby agrees to waive in any action for specific performance of any such obligation the defense that a remedy at law would be
adequate.

 

8.5.          Limitation
of Liability. Notwithstanding anything herein to the contrary, each of UCP and Kapitalacknowledges and agrees that the liability
of the Shareholder arising directly or indirectly, under any Transaction Document of any and every nature whatsoever shall be
satisfied solely out of the assets of the Shareholder, and that no trustee, officer, other investment vehicle or any other affiliate
of the Shareholder or any investor, shareholder or holder of shares of beneficial interest of the Shareholder shall be personally
liable for any liabilities of the Shareholder.

 

8.6.          Interpretation. When
a reference is made in this Agreement to a Section, such reference shall be to a Section of this Agreement unless otherwise indicated.
Whenever the words “include”, “includes” or “including” are used in this Agreement, they shall
be deemed to be followed by the words “without limitation”.

 

8.7.          Severability. If
any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule or Law, or public
policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the
economic or legal substance of the Transactions is not affected in any manner materially adverse to any Party. Upon such determination
that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith
to modify this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner to
the end that the Transactions are fulfilled to the extent possible.

  

    	-25-

    	 

    

  

8.8.          Counterparts;
Facsimile Execution. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the
same agreement and shall become effective when one or more counterparts have been signed by each of the Parties and delivered
to the other Parties. Facsimile execution and delivery of this Agreement is legal, valid and binding for all purposes.

 

8.9.          Entire
Agreement; Third Party Beneficiaries. This Agreement, taken together with the Kapital
Disclosure Letter and UCP Disclosure Letter, (a) constitute the entire agreement and supersede all prior agreements and
understandings, both written and oral, among the Parties with respect to the Transactions and (b) are not intended to confer upon
any person other than the Parties any rights or remedies.

 

8.10.         Governing
Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York, regardless of
the laws that might otherwise govern under applicable principles of conflicts of laws thereof, except to the extent the laws of
Nevada are mandatorily applicable to the Transactions.

 

8.11.         Survival. Each
of the representations and warranties made herein by UCP, Kapitaland the Shareholder shall survive the Closing for a period terminating
twenty-four months after the date of the Closing.

 

8.12.         Assignment. Neither
this Agreement nor any of the rights, interests or obligations under this Agreement shall be assigned, in whole or in part, by
operation of law or otherwise by any of the Parties without the prior written consent of each of the other Parties. Any purported
assignment without such consent shall be void. Subject to the preceding sentences, this Agreement will be binding upon, inure
to the benefit of, and be enforceable by, the Parties and their respective successors and assigns.

  

[Signature Page Follows]

 

    	-26-

    	 

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Share Exchange Agreement to be duly executed by their respective authorized signatories as
of the date first indicated above.

 

	 	UCP HOLDINGS, INC.
	 	 
	 	By:	 
	 	Name: Siva Pillarisetty
	 	Title: CFO/Secretary/Director
	 	 
	 	KAPITAL Yonetim Hizmet Ve Gayrimenkul Yatirim Sanayi Ticaret Ltd. Sirketi
    
	 	 
	 	By:	 
	 	Name: Erdogan Cetin   
	 	Title: President
	 	Address: Dereboyu Caddesi, Uphill Towers, A Block, 17th Floor, Suite:107,
    34758, Atasehir, Istanbul-Turkey
	 	 
	 	SHAREHOLDER:
	 	 
	 	 
	 	Name: Erdogan Cetin  
	 	Address: 14 Wall Street, 20th Floor, Suite:2060,New York, 10005, NY

 

    	 

    	 

    

 

ANNEXES

 

    	 

    	 

    

 

 

ANNEX A

 

Shareholder of Kapital

  

	Name and Address of Shareholder	 	Number of
 Shares of
 Kapital Stock
 Exchanged	 	 	Percentage of
 Total Shares of
 Kapital Stock	 	 	Number of
 Shares of
 UCP Stock
 Received	 
	 	 	 	 	 	 	 	 	 	 
	Erdogan Cetin
 14 Wall Street, 20th Floor, Suite:2060, New 

York, 10005, NY-US
	 	 	2,040,000,000	 	 	 	51	%	 	 	36,500,000	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	TOTAL	 	 	 	 	 	 	51	%	 	 	 	 

 

    	 

    	 

    

 

ANNEX B

 

Definitions

 

“Action”
means any action, suit, inquiry, notice of violation, proceeding (including any partial proceeding such as a deposition) or investigation
pending or threatened in writing before or by any court, arbitrator, governmental or administrative agency, regulatory authority
(federal, state, county, local or foreign), stock market, stock exchange or trading facility.

 

“Agreement”
has the meaning set forth in the Preamble of this Agreement.

 

“Closing”
has the meaning set forth in Section 1.2 of this Agreement.

 

“Closing
Date” has the meaning set forth in Section 1.2 of this Agreement.

 

“Consent”
means any material consent, approval, license, permit, order or authorization.         

 

“Contract”
means any contract, lease, license, indenture, note, bond, agreement, permit, concession, franchise or other instrument.

 

“Kapital”
has the meaning set forth in the Preamble of this Agreement.

 

“Directed
Selling Effort” has the meaning set forth in Section 2.14 of this Agreement.

 

“Environmental
Laws” has the meaning set forth in Section 3.29(c) of this Agreement.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended.

 

“Governmental
Entity” means any federal, state, local or foreign government or any court of competent jurisdiction, administrative
agency or commission or other governmental authority or instrumentality, domestic or foreign.

 

“Kapital”
has the meaning set forth in the Preamble of this Agreement.

 

“Kapital
Benefit Plans” has the meaning set forth in Section 3.7 of this Agreement.

 

“Kapital
Constituent Instruments” means the Certificate of Incorporation and Memorandum and Articles of Association of Kapital
and such other constituent instruments of Kapital as may exist, each as amended to the date of this Agreement.

 

“Kapital
Disclosure Letter” means the letter delivered from Kapital to UCP concurrently herewith.

 

“Kapital
Financial Statements” has the meaning set forth in the Section 3.15 of this Agreement.

 

    	 

    	 

    

 

“Kapital
Material Adverse Effect” has the meaning set forth in Section 3.1 of this Agreement.

 

“Kapital
Stock” has the meaning set forth in the Background Section of this Agreement.

 

“Intellectual
Property Right” means any patent, patent right, trademark, trademark right, trade name, trade name right, service mark,
service mark right, copyright and other proprietary intellectual property right and computer program.

 

“Law”
means any statute, law, ordinance, rule, regulation, order, writ, injunction, judgment, or decree.

 

“Lien”
means any lien, security interest, pledge, equity and claim of any kind, voting trust, stockholder agreement, restrictions on
transfer, adverse claims of any nature, or other encumbrance.

 

 

“Party”
has the meaning set forth in the Preamble of this Agreement.

 

“SEC”
means the Securities and Exchange Commission.

 

“SEC Reports”
has the meaning set forth in Section 4.6(a) of this Agreement.

 

“Securities
Act” means the Securities Act of 1933, as amended.

 

“Shareholder”
has the meaning set forth in the Preamble of this Agreement.

 

“Shares”
has the meaning set forth in the Background Section of this Agreement.

 

“Taxes”
means all forms of taxation, whenever created or imposed, and whether of the United States or elsewhere, and whether imposed by
a local, municipal, governmental, state, foreign, federal or other Governmental Entity, or in connection with any agreement with
respect to Taxes, including all interest, penalties and additions imposed with respect to such amounts.

 

“Tax Return”
means all federal, state, local, provincial and foreign Tax returns, declarations, statements, reports, schedules, forms and information
returns and any amended Tax return relating to Taxes.

 

“Transactions”
has the meaning set forth in Section 1.2 of this Agreement.

 

“Transaction
Documents” means this Agreement and any other documents or agreements executed in connection with the Transactions.

 

“UCP”
has the meaning set forth in the Preamble of this Agreement.

 

    	 

    	 

    

 

“UCP Benefit
Plans” has the meaning set forth in the Section 4.10 of this Agreement.

 

“UCP Bylaws”
means the Bylaws of UCP, as amended to the date of this Agreement.

 

“UCP Charter”
means the Articles of Incorporation of UCP, as amended to the date of this Agreement.

 

“UCP Disclosure
Letter” means the letter delivered from UCP to Kapital concurrently herewith.

 

“UCP Financial
Statements” has the meaning set forth in the Section 4.8 of this Agreement.

 

“UCP Material
Adverse Effect” has the meaning set forth in the Section 4.1 of this Agreement.

 

“UCP Stock”
has the meaning set forth in the Background Section of this Agreement.

 

    	 

    	 

    

 

ANNEX C

 

Accredited Investor Representations

 

Shareholder, indicating that it is an
“accredited investor” within the meaning of Rule 501 under the Securities Act (“Accredited Investor”),
further represents and warrants to UCP as follows:

 

		1.	Such person or entity
has sufficient knowledge and experience in finance, securities, investments and other business matters to be able to protect Shareholder’s
interests in connection with the transactions contemplated by this Agreement.

 

		2.	Such person or entity
has consulted, to the extent that it has deemed necessary, with its tax, legal, accounting and financial advisors concerning its
investment in the UCP Stock.

 

		3.	Such person or entity
understands the various risks of an investment in the UCP Stock and can afford to bear such risks for an indefinite period of
time, including, without limitation, the risk of losing its entire investment in the UCP Stock.

 

		4.	Such person or entity
has had access to UCP’s publicly filed reports with the SEC.

 

		5.	Such person or entity
has been furnished during the course of the transactions contemplated by this Agreement with all other public information regarding
UCP that such person or entity has requested and all such public information is sufficient for such person or entity to evaluate
the risks of investing in the UCP Stock.

 

		6.	Such person or entity
has been afforded the opportunity to ask questions of and receive answers concerning UCP and the terms and conditions of the issuance
of the UCP Stock.

 

		7.	Such person or entity
is not relying on any representations and warranties concerning UCP made by UCP or any officer, employee or agent of UCP, other
than those contained in this Agreement.

 

		8.	Such person or entity
is acquiring the UCP Stock for such person’s or entity’s, as the case may be, own account, for investment and not
for distribution or resale to others.

 

		9.	Such person or entity
will not sell or otherwise transfer the UCP Stock, unless either (a) the transfer of such securities is registered under the Securities
Act or (b) an exemption from registration of such securities is available.

 

		10.	Such person or entity
understands and acknowledges that UCP is under no obligation to register the UCP Stock for sale under the Securities Act.

 

		11.	Such person or entity
consents to the placement of a legend on any certificate or other document evidencing the UCP Stock substantially in the form
set forth in Section 2.14.

 

		12.	Such person or entity
represents that the address furnished on its signature page to this Agreement and in Annex A is the principal residence
if he is an individual or its principal business address if it is a corporation or other entity.

 

    	 

    	 

    

 

		13.	Such person or entity
understands and acknowledges that the UCP Stock has not been recommended by any federal or state securities commission or regulatory
authority, that the foregoing authorities have not confirmed the accuracy or determined the adequacy of any information concerning
UCP that has been supplied to such person or entity and that any representation to the contrary is a criminal offense.

 

		14.	Such person or entity
acknowledges that the representations, warranties and agreements made by such person or entity herein shall survive the execution
and delivery of this Agreement and the purchase of the UCP Stock.

 

    	 

    	 

    

 

ANNEX D

 

Non-U.S. Person Representations

 

Shareholder, indicating that it is not
a U.S. person, further represents and warrants to UCP as follows:

 

		1.	At the time of (a) the
offer by UCP and (b) the acceptance of the offer by such person or entity, of the UCP Stock, such person or entity was outside
the United States.

 

		2.	No offer to acquire
the UCP Stock or otherwise to participate in the transactions contemplated by this Agreement was made to such person or entity
or its representatives inside the United States.

 

		3.	Such person or entity
is not purchasing the UCP Stock for the account or benefit of any U.S. person, or with a view towards distribution to any U.S.
person, in violation of the registration requirements of the Securities Act.

 

		4.	Such person or entity
will make all subsequent offers and sales of the UCP Stock either (x) outside of the United States in compliance with Regulation
S; (y) pursuant to a registration under the Securities Act; or (z) pursuant to an available exemption from registration under
the Securities Act. Specifically, such person or entity will not resell the UCP Stock to any U.S. person or within the United
States prior to the expiration of a period commencing on the Closing Date and ending on the date that is one year thereafter (the
“Distribution Compliance Period”), except pursuant to registration under the Securities Act or an exemption from registration
under the Securities Act.

 

		5.	Such person or entity
is acquiring the UCP Stock for Shareholder’s own account, for investment and not for distribution or resale to others.

 

		6.	Such person or entity
has no present plan or intention to sell the UCP Stock in the United States or to a U.S. person at any predetermined time, has
made no predetermined arrangements to sell the UCP Stock and is not acting as an underwriter, dealer or other person who participates,
pursuant to a contractual arrangement, in the distribution of the securities offered or sold in reliance on Regulation S.

 

		7.	Neither such person
or entity, its affiliates nor any person acting on behalf of such person or entity, has entered into, has the intention of entering
into, or will enter into any put option, short position or other similar instrument or position in the U.S. with respect to the
UCP Stock at any time after the Closing Date through the Distribution Compliance Period except in compliance with the Securities
Act.

 

		8.	Such person or entity
consents to the placement of a legend on any certificate or other document evidencing the UCP substantially in the form set forth
in Section 2.14.

 

		9.	Such person or entity
is not acquiring the UCP Stock in a transaction (or an element of a series of transactions) that is part of any plan or scheme
to evade the registration provisions of the Securities Act.

 

    	 

    	 

    

 

		10.	Such person or entity
has sufficient knowledge and experience in finance, securities, investments and other business matters to be able to protect such
person’s or entity’s interests in connection with the transactions contemplated by this Agreement.

		 	 

		11.	Such person or entity
has consulted, to the extent that it has deemed necessary, with its tax, legal, accounting and financial advisors concerning its
investment in the UCP Stock.

		 	 

		12.	Such person or entity
understands the various risks of an investment in the UCP Stock and can afford to bear such risks for an indefinite period of
time, including, without limitation, the risk of losing its entire investment in the UCP Stock.

		 	 

		13.	Such person or entity
has had access to UCP’s publicly filed reports with the SEC.

		 	 

		14.	Such person or entity
has been furnished during the course of the transactions contemplated by this Agreement with all other public information regarding
UCP that such person or entity has requested and all such public information is sufficient for such person or entity to evaluate
the risks of investing in the UCP Stock.

		 	 

		15.	Such person or entity
has been afforded the opportunity to ask questions of and receive answers concerning UCP and the terms and conditions of the issuance
of the UCP Stock.

		 	 

		16.	Such person or entity
is not relying on any representations and warranties concerning UCP made by UCP or any officer, employee or agent of UCP, other
than those contained in this Agreement.

		 	 

		17.	Such person or entity
will not sell or otherwise transfer the UCP Stock, unless either (A) the transfer of such securities is registered under the Securities
Act or (B) an exemption from registration of such securities is available.

		 	 

		18.	Such person or entity
understands and acknowledges that UCP is under no obligation to register the UCP Stock for sale under the Securities Act.

		 	 

		19.	Such person or entity
represents that the address furnished on its signature page to this Agreement and in Annex A is the principal residence
if he is an individual or its principal business address if it is a corporation or other entity.

		 	 

		20.	Such person or entity
understands and acknowledges that the UCP Stock have not been recommended by any federal or state securities commission or regulatory
authority, that the foregoing authorities have not confirmed the accuracy or determined the adequacy of any information concerning
UCP that has been supplied to such person or entity and that any representation to the contrary is a criminal offense.

		 	 

		21.	Such person or entity
acknowledges that the representations, warranties and agreements made by such person or entity herein shall survive the execution
and delivery of this Agreement and the purchase of the UCP Stock.Exhibit 10.1

 

Stock Purchase Agreement

 

This Stock Purchase
Agreement (this “Agreement”) is made this 10th day of January, 2014 by and among KOFFEE KORNER INC.,
a Delaware corporation (“PubCo”), CARDAX PHARMACEUTICALS, INC., a Delaware corporation (“Holdings”),
and CARDAX PHARMA, INC., a Delaware corporation (“Pharma”).

 

WHEREAS, PubCo, CARDAX
ACQUISITION, INC., a Delaware corporation and a wholly owned subsidiary of PubCo (“PubCo Sub”), Holdings and
Pharma entered into that certain Agreement and Plan of Merger dated as of November 27, 2013, as amended on the date of this Agreement
(the “Merger Agreement”);

 

WHEREAS, as of the
date of this Agreement, Holdings owns all of the issued and outstanding shares of capital stock of Pharma, which are 100 shares
of common stock, par value $0.01 (the “Pharma Common Stock”);

 

WHEREAS, the parties
to Agreement desire that on the date of this Agreement (the “Closing Date”): (i) Pharma will issue and sell
to PubCo that number of shares of its Pharma Common Stock so that PubCo will own 40% of the issued and outstanding shares of Pharma
Common Stock, or 66.67 shares of Pharma Common Stock; and (ii) as consideration for the issuance of such shares of Pharma Common
Stock, PubCo will issue 30,000,000 shares (after giving effect to the stock dividend to stockholders of record on January 9, 2014
(the “January 9 Dividend”)) of its common stock, par value $0.0001 per share (the “PubCo Common Stock”),
which would represent approximately 39% of the issued and outstanding shares of PubCo Common Stock after such issuance;

 

WHEREAS, the aggregate
number of shares of PubCo issued and outstanding on the date of this Agreement, prior to the issuance and sale of the shares of
PubCo Common Stock under this Agreement, is 46,332,000 (or 10,530,000 prior to the stock dividend);

 

WHEREAS, the shares
of PubCo Common Stock that will be issued and sold to Pharma on the date of this Agreement are to be distributed to Holdings as
a dividend;

 

NOW, THEREFORE, for
good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties to this Agreement agree
as follows:

 

1.Stock Issuance
and Exchange.

 

1.1.Pharma hereby
agrees to issue, sell and deliver to PubCo 66.67 shares of Pharma Common Stock, which shares shall be duly and validly issued,
fully paid and nonassessable.

 

1.2. PubCo hereby
agrees to issue, sell and deliver to Pharma 30,000,000 shares of PubCo Common Stock, which shares shall be duly and validly
issued, fully paid and nonassessable, as provided in the Unanimous Written Consent of the Directors of PubCo dated as of the
date of this Agreement.

 

    	 

    	 

    

 

1.3.Upon PubCo’s
receipt of notice by Pharma that all of the shares of PubCo Common Stock issued by PubCo to Pharma under this Agreement have been
distributed as a dividend to Holdings, PubCo shall register such shares in the name of Holdings.

 

2.Representations
and Warranties.

 

2.1.Pharma hereby
represents and warrants to PubCo the following:

 

2.1.1.Pharma
is duly incorporated, organized and validly subsisting as a corporation under the laws of the State of Delaware and is duly qualified
or otherwise authorized to transact business as a foreign corporation and in good standing in each other jurisdiction in which
it owns or leases property of a nature or transacts business of a type, that would make such qualification necessary.

 

2.1.2.No
authorization, approval, consent or license of any Authority, and no authorization, approval or consent of any other person, is
required in connection with the execution and delivery by Pharma of this Agreement or the consummation and performance by Pharma
of the transactions contemplated hereby other than those which have been received on or prior to the date hereof. For the purposes
of this Agreement, the term “Authority” shall mean any nation or government, any state or other political subdivision
thereof, any entity exercising executive, legislative, judicial, regulatory or administration functions of or pertaining to government,
including, without limitation, the Securities and Exchange Commission or any other government authority, agency, department, board,
commission or instrumentality of the United States of America, any State of the United States or any political subdivision thereof,
and any court, tribunal or arbitrator(s) of competent jurisdiction, and any governmental or non-governmental self-regulatory organization,
agency or authority.

 

2.1.3.The
execution and delivery of this Agreement by Pharma, the consummation by Pharma of the transactions contemplated hereby and the
performance by Pharma of this Agreement in accordance with its terms do not and will not: (i) result in any violation of the Certificate
of Incorporation, By-Laws or any agreement of Pharma; or (ii) conflict with, or result in a breach of any of the terms or provisions
of, or constitute a default under, or result in the creation or imposition of any lien, pledge, security interest, claim, charge,
transfer restriction or similar agreement, encumbrance or other restriction or limitation whatsoever (each, a “Lien”)
upon any property or assets of Pharma under any contract, indenture, mortgage, loan agreement, note, lease or other agreement or
instrument to which Pharma is a party or by which it may be bound or to which any of its properties may be subject; or (iii) result
in any violation by Pharma of any existing applicable law, rule, regulation, judgment, order or decree of any Authority.

 

2.1.4.There
is no action, suit or proceeding before or by any Authority, now pending or, to the knowledge of Pharma, threatened against or
affecting Pharma that could have a material adverse effect on the ability of Pharma to consummate the transactions contemplated
hereby.

 

    	2

    	 

    

 

2.1.5.Pharma
has the full legal right, power and authority to enter into, execute and deliver this Agreement, to perform fully its obligations
hereunder and to issue and sell the Pharma Common Stock to PubCo. This Agreement has been duly and validly authorized by the Board
of Directors of Pharma and no other proceedings or actions on the part of Pharma are necessary to authorize this Agreement or to
perform its obligations hereunder. The shares of Pharma Common Stock issued under this Agreement are duly and validly issued, fully
paid and nonassessable and not subject to any Lien other than restrictions on the transfer under applicable law.

 

2.1.6.This
Agreement has been duly executed and delivered by Pharma and constitutes the legal, valid and binding obligation of Pharma, and
is enforceable against Pharma in accordance with its terms.

 

2.1.7.Prior
to the issuance and sale of the Pharma Common Stock under the terms of this Agreement, Holdings is the sole owner of any capital
stock of Pharma.

 

2.1.8.No
broker, finder, agent or similar intermediary has acted for or on behalf of Pharma in connection with this Agreement, and no broker,
finder, agent or similar intermediary is entitled to any broker’s, finder’s or similar fee or other commission in connection
therewith based on any agreement, arrangement or understanding with Pharma, or any action taken by Pharma.

 

2.2.PubCo hereby
represents and warrants to Pharma the following:

 

2.2.1.PubCo
is duly incorporated, organized and validly subsisting as a corporation under the laws of the State of Delaware and is duly qualified
or otherwise authorized to transact business as a foreign corporation and in good standing in each other jurisdiction in which
it owns or leases property of a nature or transacts business of a type, that would make such qualification necessary.

 

2.2.2.No
authorization, approval, consent or license of any Authority, and no authorization, approval or consent of any other person, is
required in connection with the execution and delivery by PubCo of this Agreement or the consummation and performance by PubCo
of the transactions contemplated hereby other than those which have been received on or prior to the date hereof.

 

2.2.3.The
execution and delivery of this Agreement by PubCo, the consummation by PubCo of the transactions contemplated hereby and the performance
by PubCo of this Agreement in accordance with its terms do not and will not: (i) result in any violation of the Certificate of
Incorporation, By-Laws or any agreement of PubCo; or (ii) conflict with, or result in a breach of any of the terms or provisions
of, or constitute a default under, or result in the creation or imposition of any Lien upon any property or assets of PubCo under
any contract, indenture, mortgage, loan agreement, note, lease or other agreement or instrument to which PubCo is a party or by
which it may be bound or to which any of its properties may be subject; or (iii) result in any violation by PubCo of any existing
applicable law, rule, regulation, judgment, order or decree of any Authority.

 

    	3

    	 

    

 

2.2.4.There
is no action, suit or proceeding before or by any Authority, now pending or, to the knowledge of PubCo, threatened against or affecting
PubCo that could have a material adverse effect on the ability of PubCo to consummate the transactions contemplated hereby.

 

2.2.5.PubCo
has the full legal right, power and authority to enter into, execute and deliver this Agreement, to perform fully its obligations
hereunder and to issue and sell the PubCo Common Stock to Pharma. This Agreement has been duly and validly authorized by the Board
of Directors of PubCo and no other proceedings or actions on the part of PubCo are necessary to authorize this Agreement or to
perform its obligations hereunder. The shares of PubCo Common Stock issued under this Agreement are duly and validly issued, fully
paid and nonassessable and not subject to any Lien other than restrictions on the transfer under applicable law.

 

2.2.6.This
Agreement has been duly executed and delivered by PubCo and constitutes the legal, valid and binding obligation of PubCo, and is
enforceable against PubCo in accordance with its terms.

 

2.2.7.Prior
to the issuance and sale of the PubCo Common Stock under the terms of this Agreement, and subsequent to the January 9 Dividend,
the aggregate number of the issued and outstanding shares of any capital stock of PubCo is 46,332,000 shares of PubCo Common Stock.

 

2.2.8.No
broker, finder, agent or similar intermediary has acted for or on behalf of PubCo in connection with this Agreement, and no broker,
finder, agent or similar intermediary is entitled to any broker’s, finder’s or similar fee or other commission in connection
therewith based on any agreement, arrangement or understanding with PubCo, or any action taken by PubCo.

 

3.Rescission
Right. If the merger under the terms and conditions of the Merger Agreement is not effective on or prior to 5:30 pm (Eastern
Standard Time) on January 17, 2014, then either party may, upon notice to the other party, rescind and void the issuance, sale
and exchange of the Pharma Common Stock and the PubCo Common Stock under the terms of this Agreement. Upon delivery of any such
notice, all shares of PubCo Common Stock issued and delivered to Pharma (and distributed to Holdings), shall be delivered to PubCo
for cancellation and all shares of Pharma Common Stock issued to PubCo shall be delivered to Pharma for cancellation. Upon the
delivery of such shares of common stock for cancellation, all obligations of the parties to this Agreement under the terms and
conditions of this Agreement shall be terminated and deemed discharged in full.

 

4.Ratification
of the Merger Agreement. The Merger Agreement, as amended on the date of this Agreement, is hereby ratified and confirmed and
is in full force and effect.

 

4.1.Further Actions.
At any time and from time to time, each party agrees to take such actions and to execute and deliver such documents as may be reasonably
necessary to effectuate the purposes of this Agreement.

 

    	4

    	 

    

 

4.2.Notices.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered
via facsimile at the facsimile number set forth on the signature pages attached hereto at or prior to 5:30 p.m. (Eastern Standard
Time) on a business day, (b) the next business day after the date of transmission, if such notice or communication is delivered
via facsimile at the facsimile number set forth on the signature pages attached hereto on a day that is not a business day or later
than 5:30 p.m. (Eastern Standard Time) on any business day, (c) the second (2nd) business day following the date of
mailing, if sent by United States internationally recognized overnight courier service or (d) upon actual receipt by the party
to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature
pages attached hereto. For the purposes herein, “business day” means a day that commercial banks are not authorized
to be closed for business transactions.

 

4.3.Availability
of Equitable Remedies. Since a breach of the provisions of this Agreement could not adequately be compensated by money damages,
any party shall be entitled, either before or after the effective time of the merger under the Merger Agreement (the “Effective
Time”), in addition to any other right or remedy available to it, to an injunction restraining such breach or threatened
breach and to specific performance of any such provision of this Agreement, and, in either case, no bond or other security shall
be required in connection therewith, and the parties hereby consent to the issuance of such an injunction and to the ordering of
specific performance.

 

4.4.Survival.
The covenants, agreements, representations, and warranties contained in or made pursuant to this Agreement shall survive the
Effective Time for a period of one (1) full fiscal year thereafter.

 

4.5.Modification.
This Agreement sets forth the entire understanding of the parties with respect to the subject matter hereof and supersedes all
existing agreements among them concerning such subject matter. This Agreement shall only be modified by the written agreement of
all parties.

 

4.6.Waiver.
Any waiver by any party of a breach of any term of this Agreement shall not operate as or be construed to be a waiver of any other
breach of that term or of any breach of any other term of this Agreement. The failure of a party to insist upon strict adherence
to any term of this Agreement on one or more occasions will not be considered a waiver or deprive that party of the right thereafter
to insist upon strict adherence to that term or any other term of this Agreement.

 

4.7.Binding Effect.
The provisions of this Agreement shall be binding upon and inure to the benefit of the parties and their respective successors
and assigns.

 

4.8.No Third-Party
Beneficiaries. Except as otherwise expressly provided in this Agreement, this Agreement does not create, and shall not be construed
as creating, any rights enforceable by any person not a party to this Agreement.

 

    	5

    	 

    

 

4.9.Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full
force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that
they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be
hereafter declared invalid, illegal, void or unenforceable.

 

4.10.Headings.
The headings in this Agreement are solely for convenience of reference and shall be given no effect in the construction or interpretation
of this Agreement.

 

4.11.Governing
Law.

 

4.11.1.All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed
and enforced in accordance with the internal laws of the State of Delaware. Each party agrees that all legal proceedings concerning
the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party
hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be, except
to the extent otherwise required by applicable law, commenced exclusively in the state and federal courts sitting in the City of
New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City
of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein (including with respect to the enforcement of any provision of this Agreement), and hereby
irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to
the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding.

 

4.11.2.Each
party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding
by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the
address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service
of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other
manner permitted by law.

 

4.11.3.If
one or more parties shall commence an action, suit or proceeding to enforce any provision of this Agreement, the prevailing party
or parties in such action, suit or proceeding shall be reimbursed by the other party or parties to such action, suit or proceeding
for the reasonable attorneys’ fees and other costs and expenses incurred by the prevailing party or parties with the investigation,
preparation and prosecution of such action, suit or proceeding.

 

    	6

    	 

    

 

4.12.WAIVER OF
JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES
EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY
AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.

 

4.13.Execution.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being
understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf”
signature page were an original thereof.

 

 

 

 

[REMAINDER OF PAGE INTENTIONALLY LEFT
BLANK;

SIGNATURE PAGE FOLLOWS]

 

    	7

    	 

    

 

IN WITNESS WHEREOF, this Agreement
has been executed by duly authorized officers of each of the parties hereto as of the date first above written.

 

 

 

	 	KOFFEE KORNER INC.	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Austin Kibler	 
	 	 	Name:
    Austin Kibler	 
	 	 	Title:
    Managing Member	 
	 	 	 	 
	 	 	 	 
	 	Cardax
Pharmaceuticals, Inc.	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/ David G. Watumull	 
	 	 	Name:
    David G. Watumull	 
	 	 	Title:
    President and CEO	 
	 	 	 	 
	 	 	 	 
	 	CARDAX PHARMA, INC.	
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/ David G. Watumull	 
	 	 	Name:
    David G. Watumull	 
	 	 	Title:
    President and CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]